NEWARK, Calif., July 21, 2011 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEMD), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, announced today that it has received notification from The NASDAQ Stock Market that the Company has regained compliance with the minimum bid price requirement. In order to continue listing on the NASDAQ Global Market, the NASDAQ Listing Rules require the Company's stock to evidence a closing bid price of $1.00 per share or more for ten consecutive days. On July 20, 2011, the closing bid price of the Company's common stock was $3.75 per share, the tenth consecutive day the bid price closed above $1.00 per share.
